Pulmonary Embolism

68

Pipeline Programs↗

22

Active Trials↗

23

Companies Involved↗

Pulmonary Embolism is a moderately active landscape with 68 programs across 23 companies. The most active players are Viatris Specialty LLC, Angde Biotech Pharmaceutical Co., Ltd., Tasly Biopharmaceuticals Co., Ltd.. 26 therapies are approved with 16 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

66/100

Pipeline Velocity

11/100

Mech. Concentration

21/100

Completion Rate

81/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Viatris Specialty LLC

1 program

Angde Biotech Pharmaceutical Co., Ltd.

2 programs

Tasly Biopharmaceuticals Co., Ltd.

1 program

Lee's Pharmaceutical Limited

1 program

Eli Lilly

2 programs

Sanofi

7 programs

Pipeline

Programs by Phase

Preclinical13

Fondaparinux

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Enoxaparin Sodium

Sanofi

Fondaparinux Sodium

GSK

Semaglutide

Novo Nordisk

Warfarin Sodium

Boehringer Ingelheim

Phase 15

Nitric Oxide

Mallinckrodt

Sildenafil

Viatris Specialty LLC

OXYGEN THERAPY

Massachusetts General Hospital

Standard ADT Treatment

RenJi Hospital

Sildenafil/apixaban

Meshalkin Research Institute of Pathology of Circulation

Phase 28

Enoxaparin

Sanofi

Inhaled Nitric Oxide

Lee's Pharmaceutical Limited

TS23

Translational Sciences, Inc.

Drotrecogin Alfa Activated

Eli Lilly

Ds-1040b

Daiichi Sankyo

Phase 316

Tenecteplase

Roche

Alteplase

Roche

Heparin

Baxter Healthcare Corporation

Low-Molecular-Weight Heparin

Daiichi Sankyo

Avidin

Sanofi

Approved26

Rivaroxaban

Wim Janssens

Furosemide

Validus Pharmaceuticals

Warfarin

Abbott

Macitentan

Johnson & Johnson

Apixaban

Bristol-Myers Squibb

Analysis

Modality Breakdown

85%

Small molecule

67 of 79 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 79 classified programs, each share of the total. Modality classified for 99% of 82 pipeline programs.

Analysis

Trial Status

87

clinical trials

Completed44 · 51%

Recruiting14 · 16%

Unknown status11 · 13%

Terminated7 · 8%

Not yet recruiting4 · 5%

Active, not recruiting4 · 5%

Other3 · 3%

Clinical Trials

Trial Activity

87 trials

'Thrombectomy in High-Risk Pulmonary Embolism - Device Versus Thrombolysis Netherlands': TORPEDO-NL

Recruiting·LLeiden University Medical Center·N/A·NCT06833827·111 enrolled

Non-immunogenic Recombinant Staphylokinase vs Placebo in Patients With Intermediate High-risk Pulmonary Embolism

Recruiting·SSupergene, LLC·Phase 3·NCT06362746·486 enrolled

Catheter-directed Thrombolysis in Intermediate-high Risk Acute Pulmonary Embolism

Recruiting·FFaculty Hospital Kralovske Vinohrady·Phase 4·NCT05493163·558 enrolled

Early Catheter-directed Treatment of High Risk Pulmonary Embolism

Recruiting·LLeipzig Heart Science gGmbH·N/A·NCT06672081·210 enrolled

Supplemental Oxygen in Pulmonary Embolism (SO-PE)

Recruiting·MMassachusetts General Hospital·Phase 1·NCT05891886·80 enrolled

Pulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy

Recruiting·NNYU Langone Health·Phase 3·NCT05591118·500 enrolled

Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism

Recruiting·—·Phase 4·NCT04263038·276 enrolled

Evaluation of the Standard Catheter-directed Thrombolysis Effectiveness in Intermediate-High-Risk Pulmonary Embolism Patients

Recruiting·Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health·N/A·NCT06487052·100 enrolled

Reperfusion Treatment in Acute Pulmonary Embolism

Recruiting·SSahlgrenska University Hospital·N/A·NCT07003646·220 enrolled

Is Clonal Hematopoiesis of Indeterminate Potential Associated With Unprovoked Pulmonary Embolism?

Recruiting·—·N/A·NCT04711746·544 enrolled

Inari VISION Registry

Recruiting·IInari Medical·N/A·NCT06600542·1,000 enrolled

The PERSEVERE Study

Recruiting·IInari Medical·Preclinical·NCT06588634·200 enrolled

STRIKE-PE: A Prospective, Multicenter Study of the Indigo™ Aspiration System Seeking to Evaluate the Long-Term Safety and Outcomes of Treating Pulmonary Embolism

Recruiting·PPenumbra Inc.·N/A·NCT04798261·1,500 enrolled

Percutaneous Embolectomy, Low Dose Thrombolysis or Heparin for Intermediate High Risk Pulmonary Embolism (STRATIFY II)

Recruiting·—·Phase 3·NCT06453876·210 enrolled

Low Dose Thrombolysis, Ultrasound Assisted Thrombolysis or Heparin for Intermediate High Risk Pulmonary Embolism

Active, not recruiting·—·Phase 3·NCT04088292·210 enrolled

Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)